1 The present study investigated the role of second messenger-dependent protein kinase A (PKA) and C (PKC) in the regulation of endogenous secretin receptor responsiveness in NG108-15 mouse neuroblastoma6rat glioma hybrid cells. 2 In whole cell cyclic AMP accumulation studies, activation of PKC either by phorbol 12-myristate 13-acetate (PMA) or by purinoceptor stimulation using uridine 5'-triphosphate (UTP) decreased secretin receptor responsiveness. PKC activation also inhibited forskolin-stimulated cyclic AMP accumulation but did not aect cyclic AMP responses mediated by the prostanoid-IP receptor agonist iloprost, or the A 2 adenosine receptor agonist 5'-(N-ethylcarboxamido) adenosine (NECA). 3 In additivity experiments, saturating concentrations of secretin and iloprost were found to be additive in terms of cyclic AMP accumulation, whereas saturating concentrations of NECA and iloprost together were not. This suggests compartmentalization of G s -coupling components in NG108-15 cells and possible heterologous regulation of secretin receptor responsiveness at the level of adenylyl cyclase activation. 4 Cells exposed to the PKA inhibitor H-89, exhibited a time-dependent increase in secretin receptor responsiveness compared to control cells. This eect was selective since cyclic AMP responses to forskolin, iloprost and NECA were not aected by H-89 treatment. Furthermore, treatment with the protein synthesis inhibitor cycloheximide produced a time-dependent increase in secretin receptor responsiveness. 5 Together these results indicate that endogenous secretin receptor responsiveness is regulated by PKC, PKA and protein neosynthesis in NG108-15 cells.
Introduction
Desensitization is a ubiquitous property of G protein-coupled receptors (GPCRs) and involves loss of agonist-induced receptor responsiveness. The molecular mechansims involved in GPCR desensitization are dynamically regulated and best characterized for the class I rhodopsin/b-adrenoceptor family of GPCRs, where the importance of receptor phosphorylation has been established (Hausdor et al., 1990) . GPCR phosphorylation involves two dierent families of serine/ threonine protein kinases, G protein receptor kinases (GRKs) and second messenger-dependent protein kinases, which dictate distinct pathways of signal termination (Bunemann & Hosey, 1999) . In homologous desensitization, only the agonist-occupied receptor is phosphorylated by GRKs which facilitates the binding of arrestin proteins and endocytic internalization of the receptor (Krupnick & Benovic, 1998) . In contrast, second messenger-dependent protein kinases regulate heterologous desensitization involving both active and unstimulated receptors. Protein kinases A (PKA) and C (PKC) are predominantly involved in this mode of desensitization.
The secretin receptor is a prototypic example of the structurally distinct class II subtype of GPCRs. Other members of the class II subtype include receptors for pituitary adenylate cyclase-activating polypeptide (PACAP), calcitonin, parathyroid hormone, and vasoactive intestinal hormone (Ulrich et al., 1998) . There is physiological evidence that members of the secretin receptor family exhibit agonistinduced desensitization, however, the signalling processes underlying this desensitization are not clearly understood (Holtmann et al., 1996) . In terms of physiological signi®-cance, the gastrointestinal hormone secretin is the principal stimulant of pancreatic and biliary bicarbonate and water secretion (Rausch et al., 1985) . Secretin binding sites and secretin itself have been demonstrated in the nervous system of several mammalian species and in speci®c rat brain areas (Fremeau et al., 1983; Gossen et al., 1990) , strongly suggesting a neuromodulatory role for secretin receptors.
Secretin has also been clinically tested as a possible treatment for autism (Horvath et al., 1998) . The physiological eects of secretin receptor activation are mediated through G s and G qcoupled signalling pathways (Ulrich et al., 1998) .
Agonist-stimulated phosphorylation is likely to represent an important molecular mechanism for secretin receptor desensitization in a manner analagous to the b 2 -adrenoceptor (Ozcelebi et al., 1995) . Both GRK-and second messengerdependent protein kinase-mediated phosphorylation of the receptor has been observed in various recombinant systems (Shetzline et al., 1998) . GRK-speci®c phosphorylation has been shown to correlate with rapid attenuation of secretin receptor signalling in HEK293 cells (Shetzline et al., 1998) , whilst PKA-mediated phosphorylation is thought to promote agonist-stimulated internalization of secretin receptors in the same cells (Walker et al., 1999) . The NG108-15 cell line endogenously expresses secretin receptors (Gossen et al., 1990) and provides a convenient system to study functional desensitization of the receptor in a physiological environment. This cell line also expresses other endogenous receptors including a 2 -adrenoceptors and IP-prostanoid receptors (Hamprecht, 1977) . Previous studies on secretin receptor desensitization in NG108-15 cells have suggested the involvement of GRKs in homologous desensitization of the receptor. Although over-expression of GRK2 does not aect secretin receptor responsiveness , attenuation of secretin receptor signalling was directly related to the level of GRK6 overexpression (Willets et al., 2000) . The main aim of the present study was to investigate the potential roles of PKA and PKC in heterologous desensitization of natively-expressed secretin receptors. ) was obtained from Amersham International plc. Cell culture medium and supplements were from GIBCO BRL. N-(2-[p-bromocinnamylamino]ethyl)-5-isoquinolinesulphonamide hydrochloride (H-89), 1-(5-isoquinolinesulphonyl)-2-methylpiperazine dihydrochloride (H-7), phorbol-12-myristate-13-acetate (PMA) and GF109203X (bisindolylmaleimide I) were obtained from Tocris Cookson. Adenosine 3'5'-cyclic monophosphorothioate, Rp-isomer (Rp-cyclic AMPS) was from Calbiochem. All other reagents and drugs were from Sigma Chemical Co.
Methods

Materials
Cell culture
NG108-15 mouse neuroblastoma6rat glioma hybrid cells were cultured in Dulbecco's modi®ed Eagle's medium (DMEM) containing 6% foetal calf serum, 100 u ml 71 penicillin and 100 mg ml 71 streptomycin. The culture medium was supplemented with 1 mM aminopterin, 100 mM hypoxanthine and 16 mM thymidine. Cells were maintained at 378C in humidi®ed conditions under 5% CO 2 .
Whole cell cyclic AMP accumulation NG108-15 cells were seeded in Corning 24-well microtiter plates and used at 470% con¯uence on the experimental day. One hour before the experiment, the cell culture medium was replaced with 0.5 ml of fresh culture medium, and 15 min before agonist addition the phosphodiesterase inhibitor 4-(3-butoxy-4-methoxybenzyl)imidazolinidin-2-one (Ro201724; 250 mM) was added to each well to prevent degradation of the cyclic AMP generated during the incubation period. In pre-incubation studies, PKA inhibitors H-89 (10 mM) and H-7 (150 mM), cyclic AMP antagonist Rpcyclic AMPS (50 mM), PKC inhibitor GF109203X (2 mM), PKC activator PMA (1 mM) and purinergic agonist uridine 5'-triphosphate (UTP; 100 mM) were added to wells 15 ± 30 min prior to agonist addition. Unless drug concentrations are otherwise stated, secretin (100 nM), forskolin (10 mM), 5'-(Nethylcarboxamido) adenosine (NECA; 10 mM), iloprost (a prostacyclin analogue; 1 mM) or vehicle was added to each well at time point 0 and the cell plate returned to the incubator. At various time points thereafter, 20 ml of 100% trichloroacetic acid was added to terminate the signalling reaction. To assay whole cell cyclic AMP accumulation in each well, 50 ml of the supernatant was added to 50 ml of 1 M NaOH and 200 ml of TE buer (50 mM Tris, 4 mM EDTA, pH 7.4). 100 ml of this solution was then added to LP4 tubes containing 50 ml of TE buer, 100 ml of [ 3 H]-cyclic AMP in TE buer (*20,000 c.p.m.), and 100 ml of binding protein in TE buer prepared from bovine adrenal cortex (®nal concentration of *750 mg of protein ml
71
). Cyclic AMP concentrations were measured in a competition assay as previously described , protein content of cell monolayers determined (Bradford, 1976) and cyclic AMP accumulation expressed as pmol cyclic AMP min 71 mg 71 protein.
Intracellular calcium measurements
Intracellular calcium mobilization was measured in con¯uent monolayers of NG108-15 cells using the¯uorescent Ca 2+ dye fura-2 (Connor & Henderson, 1996) . Brie¯y, cells were seeded onto poly-L-lysine-treated (0.1 mg ml
71
) plastic slides and cultured in Leighton tubes. On the experimental day, the cells were washed three times with buer (containing (mM): NaCl 130, KCl 5.5, CaCl 2 2.5, MgCl 2 1.25, HEPES 20, glucose 10, sucrose 40 and BSA 0.05%, pH 7.3) and then incubated with the acetyl methoxy-ester of fura-2 (fura-2 AM; 3 mM) for 1 h at 378C. After fura-2 loading, the plastic slides were cut in half and half was placed on a specially constructed block ®tted inside a quartz cuvette. The cuvette was placed in a LS-5B Perkin-Elmer spectro¯uorimeter and perfused with buer (4 ml min 71 at 378C). Drugs were added directly to the perfusion buer. The spectro¯uorimeter was controlled by a Perkin-Elmer software package on a computer. The fura-2 loaded cells were alternately exposed to light at 340 and 380 nm and the emission of the cells at 510 nm was recorded. Results for intracellular calcium measurements were expressed as un-calibrated 340/380 nm ratios, since these particular experiments were undertaken to provide a qualitative insight into the Ca 2+ -signalling properties of agonist stimulation in NG108-15 cells.
to ®t a sigmoidal curve of variable slope), for single-site analysis using GraphPad Prism (GraphPad Software, San Diego, CA, U.S.A.). Time-course assays were constructed using point to point measurements. Results were expressed as either fold-stimulation over basal cyclic AMP accumulation or fraction of control agonist response. Where appropriate, statistical signi®cance of dierent values were assessed by a one-sample t-test, paired t-test or two-way ANOVA using GraphPad Prism Software, statistically signi®cant dierences being assumed where P50.05.
Results
Regulation of secretin receptor responsiveness by PKC
In whole cells, secretin elicited a signi®cant enhancement in cyclic AMP generation with a 3 ± 4 fold increase in accumulation being observed after 30 min of secretin stimulation ( Figure 1A control). The secretin receptor appeared to exhibit rapid and complete agonist-mediated desensitization during continuous application of agonist, since cyclic AMP accumulation levelled o after 15 ± 30 min of agonist stimulation (t1 2 5 ± 10 min). Agonist-mediated desensitization of the secretin receptor was also observed in agonist pretreatment studies; in cells which had been pretreated with secretin for 15 min, washed and then rechallenged with secretin for a further 15 min, cyclic AMP accumulation was only 49+8% that of the control nondesensitized response (n=8). The involvement of endogenous PKC activity in secretin receptor desensitization was investigated using GF109203X, an inhibitor of conventional and novel PKC isoforms (Toullec et al., 1991) . Figure 1A shows that there was no dierence in the time-course pro®le of secretin-mediated cyclic AMP accumulation in both control and GF109203X (2 mM)-treated responses. Hence, endogenous PKC activity does not appear to regulate secretin receptor responsiveness in NG108-15 cells.
Phorbol ester treatment can induce heterologous desensitization of some GPCRs via PKC activation (Sibley et al., 1987; Hipkin et al., 2000) . In the present study, NG108-15 cells treated with the potent and cell-permeable phorbol ester PMA showed a concentration-dependent decrease in secretin receptor responsiveness ( Figure 1B ; PMA treatment did not aect basal-stimulated cyclic AMP accumulation which was 101+9% that of the control response; n=3). The selectivity of PMA was investigated by assessing the eect of PMA on cyclic AMP responses stimulated by activation of secretin and other endogenous receptors, or directly by forskolin. Pretreatment with 1 mM PMA for 15 min signi®cantly decreased 100 nM secretin-stimulated cyclic AMP accumulation ( Figure 1C ). Interestingly, forskolin-stimulated cyclic AMP accumulation was also decreased in the presence of PMA. In contrast, cyclic AMP responses to 10 mM NECA (an A 2 adenosine receptor agonist) or 1 mM iloprost (an IPprostanoid receptor agonist), were unaected by PMA treatment. Concentration-eect curves for NECA and iloprost showed no eect of PMA over a range of agonist concentrations when compared to control responses (data not shown). Thus, PMA treatment selectively inhibited secretin and forskolin responsiveness and furthermore, this inhibition was reversed upon co-addition of GF109203X indicating that PMA-induced PKC activation is the mechansim involved ( Figure 1C ).
Dual signalling properties of secretin receptor activation involving cyclic AMP and PLC-coupled pathways have been reported in certain cell lines (Ulrich et al., 1998) . In the present study, application of secretin (100 nM) to con¯uent monolayers of cells did not evoke intracellular Ca 2+ mobilization when assayed using fura-2¯uorescence ( Figure  2A ). Likewise, forskolin alone (10 mM), did not aect intracellular Ca 2+ mobilization. G q -coupled purinoceptors which couple to PKC have been characterised in NG108-15 cells (Lustig et al., 1993; Matsuoka et al., 1995) , providing a receptor system for potential cross-talk with the secretin signalling pathway. In the present study, purinergic signalling in NG108-15 cells was characterized using various purinergic agonists. Purinoceptor stimulation showed a preferential activation by trinucleophosphates since application of UTP (100 mM) and ATP (100 mM) resulted in a rapid and transient elevation of intracellular Ca 2+ , however, Ca 2+ mobilization was not evident in response to ADP (100 mM) ( Figure 2B ). In order to investigate potential cross-desensitization of secretin receptor responsiveness by purinoceptor activation, cells were pretreated with UTP (100 mM; 15 min) prior to agonist challenge and cyclic AMP accumulation measured. UTP treatment did not aect basal-stimulated cyclic AMP accumulation which was 98+1% that of the control response (n=7). In a manner analagous to PMA, UTP selectively attenuated secretin-and forskolin-stimulated cyclic AMP accumulation, without aecting adenosine A 2 or IP-prostanoid receptor responsiveness ( Figure 2C ). The ability of UTP to inhibit secretin and forskolin reponsiveness was blocked by co-addition of GF109203X ( Figure 2C ). Thus, activation of PKC either by phorbol ester treatment or purinoceptor stimulation heterologously regulates endogenous secretin receptor responsiveness.
The observation that PMA-and UTP-stimulated PKC activation selectively inhibited secretin-and forskolinmediated responses without aecting responsiveness to adenosine A 2 or IP-prostanoid receptor activation, raised the possibility that the endogenous G s -coupled receptors may be coupled to dierent adenylyl cyclase isoforms. To investigate this, additivity experiments were performed whereby agonists at maximally eective concentrations were simultaneously added to cells and cyclic AMP accumulation measured. The combination of saturating concentrations of iloprost (1 mM) and NECA (80 mM) displayed no additivity in terms of cyclic AMP accumulation when compared to the control agonist responses alone (values were 27.2+2.0, 30.9+3.3 and 26.8+2.0 fold stimulation over basal for iloprost, NECA and co-addition of iloprost and NECA, respectively, n=6; Figure 3 ). In contrast, the action of a saturating concentration of secretin (1 mM) was signi®cantly (P50.05) increased in an additive fashion by co-addition of iloprost to the cells (cyclic AMP accumulation values were 10.8+2.7, 27.2+2.0 and 39+3.3 fold stimulation over basal for secretin, iloprost and co-addition of secretin and iloprost, respectively, n=6; Figure 3) . In fura-2¯uorescence studies, drugs were perfused for the duration of the bars. The data shown are representative traces from three independent experiments giving similar results, irrespective of the order of drug addition. (C) Eect of UTP (100 mM) on agoniststimulated cyclic AMP accumulation. Cells were incubated with UTP for 15 min prior to and then during agonist challenge with secretin (100 nM), forskolin (10 mM), NECA (10 mM) or iloprost (1 mM). The last two bars represent data obtained for cells which have been pretreated with 2 mM GF109203X for 15 min prior to co-addition of UTP and secretin or forskolin. Data are mean+s.e.mean (bars) from 13 ± 16 independent experiments, each performed in quadruplicate. Cyclic AMP accumulation in the presence of UTP was expressed as a per cent of the control agonist responses. **P50.01, ***P50.001 versus respective controls, one sample t-test.
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Regulation of secretin receptor responsiveness R.S. Ghadessy & E. Kellynegative feedback mechanism to decrease receptor responsiveness. Over time, secretin-stimulated cyclic AMP accumulation was increased in the presence of the PKA inhibitor H-89 (10 mM) when compared with vehicle control (P50.05; Figure 4A ). Using a 60 min time-point of agonist stimulation, H-89 increased secretin-stimulated cyclic AMP accumulation in a concentration-dependent manner with an EC 50 value of 19.8+6.1 nM ( Figure 4A inset; this value is consistent with that reported for H-89-mediated inhibition of PKA activity (Chijiwa et al., 1990) ). Concentration-eect curves were generated to investigate the eect of H-89 over the full range of secretin concentrations ( Figure 4B ). There was no dierence in the EC 50 value for secretin-mediated cyclic AMP accumulation between control-and H-89-treated curves (29+21 and 7+4 nM, respectively), but the maximum response to secretin was increased (P50.05) in the presence of H-89 ( Figure 4B ). Treatment of the cells with another PKA inhibitor, H-7 (150 mM) and a cyclic AMP antagonist Rp-cyclic AMPS (50 mM), similarly resulted in an increase in secretin-stimulated cyclic AMP accumulation (cyclic AMP accumulation in the presence of H-7 and Rp-cyclic AMPS was 124+2 and 196+11%, that of the control secretin response, respectively; 120 min time-point, n=3 ± 5).
The selectivity of PKA in regulating adenylyl cyclase responses in NG108-15 cells was next examined. Treatment with H-89 (10 mM) enhanced secretin-stimulated cyclic AMP accumulation after 60 min of agonist stimulation to 176+21% that of the control response ( Figure 5 ). In contrast, cyclic AMP responses stimulated by forskolin, NECA and iloprost were not aected by PKA inhibition (cyclic AMP accumulation in the presence of H-89 was 104+18, 128+15 and 118+32%, versus controls, respectively). Hence, these studies with H-89 indicate a selective role of PKA in the regulation of secretin receptor responsiveness. (8) Regulation of secretin receptor responsiveness R.S. Ghadessy & E. Kellyexhibited no dierence in the EC 50 value for secretinmediated cyclic AMP accumulation between control-and cycloheximide-treated curves (15+5 and 10+3 nM, respectively; n=4). The concentration-eect curve for secretinmediated cyclic AMP accumulation was signi®cantly (P50.05) increased in the presence of cycloheximide over the range of secretin concentrations tested. After 120 min of agonist stimulation, secretin-stimulated cyclic AMP accumulation in the presence of cycloheximide was greatly enhanced to 323+61% of control ( Figure 6B ). Cycloheximide also increased cyclic AMP accumulation mediated by forskolin, iloprost and NECA, however these increases were much smaller than that observed with secretin (at 120 min cyclic AMP accumulation was 128+24, 176+6 and 154+25%, that of the control agonist responses for forskolin, iloprost and NECA, respectively; Figure 6B ).
Involvement of protein synthesis in the secretin signalling pathway
Discussion
The present study demonstrates the involvement of both second messenger-dependent kinases PKA and PKC in distinct molecular mechanisms of endogenous secretin receptor regulation. In NG108-15 cells, the endogenous secretin receptor appears to exhibit robust agonist-induced desensitization, since secretin-stimulated cyclic AMP accumulation did not increase further after 15 min. This time frame for desensitization is consistent with that reported for the heterologously-expressed secretin receptor (Shetzline et al., 1998) . However, a role for phosphodiesterase activity in contributing to the plateau in secretin receptor-stimulated cyclic AMP accumulation cannot at present be excluded. The phosphodiesterase inhibitor Ro201724 used in the experiments is a selective inhibitor of phosphodiesterase IV (IC 50 2 mM; Sheppard et al., 1972) , but its inclusion is necessary since it is dicult to detect secretin-stimulated cyclic AMP accumulation in the absence of the phosphodiesterase inhibitor (unpublished observations). However, phosphodiesterase activity mediated by other isoenzymes appears unlikely to play a predominant role in the waning of the secretin cyclic AMP response since we have found cyclic AMP accumulation in NG108-15 cells to increase robustly for up to an hour in the presence of forskolin and Ro201724 (Willets et al., 1999) .
The potential involvement of PKC in regulating secretin receptor responsiveness was ®rst examined using PMA, which inhibited responses to secretin and forskolin whilst having no eect on responses mediated by either NECA or iloprost. NECA is an A 2 adenosine receptor agonist and PMAinduced PKC activation does not regulate A 2 adenosine receptor responsiveness in NG108-15 cells (Krane et al., Figure 5 H-89 treatment selectively increases secretin receptormediated cyclic AMP response in NG108-15 cells. Cells were treated with 10 mM H-89 for 30 min prior to and during addition of either secretin (100 nM), forskolin, (10 mM), NECA (10 mM) or iloprost (1 mM) for 60 min. Data are mean+s.e.mean (bars) from ®ve independent experiments, each performed in triplicate. Cyclic AMP accumulation was expressed as a per cent of the respective control agonist responses. *P50.05, versus respective control, one sample t-test. Figure 6 Eect of protein synthesis inhibitor cycloheximide (20 mg ml 71 ) on (A) time-course of secretin-stimulated (100 nM) cyclic AMP accumulation and (B) cyclic AMP accumulation stimulated by secretin (100 nM), forskolin (10 mM), NECA (10 mM) or iloprost (1 mM). Cells were treated with cycloheximide for 30 min prior to and then during agonist stimulation for the time periods speci®ed. All data are mean+s.e.mean (bars) from at least three independent experiments, each performed in quadruplicate. (A) Over time, secretin-stimulated cyclic AMP accumulation was signi®cantly increased in the presence of cycloheximide when compared to control (P=0.0136, two-way ANOVA). (B) Secretin-stimulated cyclic AMP accumulation was signi®cantly enhanced at both 60 and 120 min time points of agonist stimulation in the presence of cycloheximide. *P50.05, versus respective controls, one sample t-test.
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Regulation of secretin receptor responsiveness R.S. Ghadessy & E. Kelly1994). Instead, short-term desensitization of these receptors is thought to occur by homologous mechanisms involving GRK2 . Prostanoid-IP receptors are proposed to desensitize via down-regulation of the receptor protein and G sa from the cell surface in NG108-15 cells, without the involvement of PKC (Krane et al., 1994; Williams & Kelly, 1994) . In the present study, the lack of eect of PKC activation on desensitization of A 2 adenosine and prostanoid-IP receptors was therefore consistent with previous reports. The PMA-induced inhibition of the secretin signalling observed in the present study may be due to direct phosphorylation of the receptor by PKC. Phosphorylation of secretin receptors expressed in HEK293 cells following PKC activation has been reported (Shetzline et al., 1998) , consistent with the existence of three consensus sites for phosphorylation by PKC within the intracellular loops of the receptor (Ulrich et al., 1998) . Studies with other class II GPCRs show that PKC activation is involved in heterologous regulation of glucagon, parathyroid and PACAP-stimulated adenylyl cyclase responses (Murphy et al., 1987; Blind et al., 1996; Muller et al., 1998) . In the present study, the forskolinmediated adenylyl cyclase response was also decreased following PMA treatment suggesting that secretin receptor signalling may also be heterologously regulated by PKCinduced changes in adenylyl cyclase activity in NG108-15 cells. These cells are thought to possess predominantly the Ca 2+ -inhibitable AC type VI isoform (Matsuoka et al., 1995) which can be phosphorylated and inhibited by PKC (Lai et al., 1997; . PKC activation has been shown to inhibit AC type VI activity during desensitization of the A 2A adenosine receptor-mediated cyclic AMP response in PC12 cells (Lai et al., 1997) . That only the secretin-and forskolinmediated responses were inhibited by PKC activation is intriguing, and suggests that the endogenous receptors may display preferential coupling to adenylyl cyclase isoforms in NG108-15 cells. Secretin-and forskolin-stimulated responses may be mediated partly through a subset of PKC-sensitive adenylyl cyclase isoforms, whereas A 2 adenosine and prostanoid-IP receptor activation may signal through a pool of PKC-insensitive adenylyl cyclase isoforms (which would also be sensitive to forskolin). This possibility was supported by the additivity experiments in which the actions of secretin and iloprost were addititive in terms of cyclic AMP accumulation. Compartmentalization of G s -coupling components has been proposed as a possible explanation for the association of adenylyl cyclase isoforms with a speci®c receptor in certain systems (Hanoune & Defer, 2001) . Indeed recently the presence of hormone-speci®c subtypes of adenylyl cyclase in the rat liver, with the secretin receptor linked only to a Ca 2+ -calmodulin-sensitive adenylyl cyclase has been reported (Yamatani et al., 2001) . Hence the PMAinduced desensitization of secretin receptor responsiveness may be due to direct phosphorylation of the receptor by PKC and/or heterologous regulation by a cognate adenylyl cyclase isoform.
The potential involvement of PKC activation in crossdesensitization of secretin receptor responsiveness was also investigated following purinoceptor activation. The G qcoupled purinoceptors characterized in the fura-2¯uores-cence studies in the present study, ®t a P 2 -Y 2 -like receptor pro®le, consistent with previous reports on purinoceptor signalling in NG108-15 cells (Lustig et al., 1993; Matsuoka et al., 1995) . In a manner analagous to PMA, the purinergic agonist UTP selectively desensitized secretin and forskolinmediated responses, without aecting A 2 adenosine or IPprostanoid responsiveness. The cross talk between purinergic and secretin receptor signalling observed in the present study could have physiological relevance in tissues such as rat pancreatic ducts where both receptors are known to be coexpressed (Christoersen et al., 1998) .
The regulation of secretin receptor responsiveness by PKC was only evident upon exogenous stimulation of PKC by PMA or UTP, as treatment with GF109203X did not aect the pro®le of secretin receptor stimulation of cyclic AMP accumulation. Relative to cyclic AMP stimulation, high concentrations of secretin have been shown to stimulate inositol trisphosphate (IP 3 ) production with subsequent activation of PKC (Trimble et al., 1987) . The ®ndings from the present study suggest that this G q -mediated pathway is not involved in secretin signalling in NG108-15 cells, perhaps because of the relatively low levels of endogenous secretin receptor expression (Gossen et al., 1990) .
In contrast to PKC, PKA appears to play an important role in modulating secretin receptor responsiveness following secretin receptor activation in NG108-15 cells. Pretreatment with the PKA inhibitors H-89 or H-7, or the cyclic AMP antagonist Rp-cyclic AMPS, resulted in enhanced cyclic AMP responses to secretin after longer time periods of agonist stimulation. As H-7 and H-89 are both isoquinolinebased PKA inhibitors, it is unclear as to why the eect of H-7 was less than that of H-89 in potentiating cyclic AMP responses to secretin. The K i of H-7 for PKA inhibition is less than that of H-89 (3 mM and 0.0048 mM, respectively; Chijiwa et al., 1990; Quick et al., 1992) , therefore we used a higher concentration of H-7 than H-89 in the present study (150 and 10 mM, respectively). One possibility is that the higher concentration of H-7 may have led to other eects on secretin receptor signalling, perhaps involving the activity of other protein kinases. The results concerning PKA inhibition dier from previous ®ndings in HEK293 cells in which PKA did not aect secretin receptor signalling, but was instead proposed to be involved in receptor internalization (Shetzline et al., 1998; Walker et al., 1999) . However, these studies used heterologously expressed secretin receptors and the authors only measured acute eects (530 min) of H-89 treatment on secretin receptor responsiveness. In NG108-15 cells, the downstream activation of PKA arising from secretinstimulated cyclic AMP accumulation may serve as a mechanism of negative feedback control to prevent overstimulation of secretin signalling pathways. Feedback regulation by second-messenger kinases activated by a particular receptor is an established mechanism for desensitizing GPCRs, as ®rst documented for the b 2 -adrenoceptor (Lefkowitz, 1998) . It is feasible that PKA-mediated phosphorylation of the secretin receptor itself is involved in receptor desensitization since PKA-mediated phosphorylation of the secretin receptor has been demonstrated in HEK293 cells (Shetzline et al., 1998) , consistent with the existence of two putative sites for phosphorylation by PKA located within the intracellular regions of the receptor (Walker et al., 1999) . Also, the present study suggests that PKA is selectively regulating secretin receptor signalling at the level of the receptor itself, as adenylyl cyclase responses to forskolin, iloprost and NECA were unaected by PKA inhibition. It has been reported that forskolin-mediated PKA activation can heterologously regulate A 2 adenosine and prostanoid IP receptor desensitization, however, these eects were only observed after 17 h of forskolin treatment and were consistent with a decrease in receptor expression (Keen et al., 1992; Krane et al., 1994) . As secretin partly exerts its physiological eects via stimulation of adenylyl cyclase with subsequent activation of PKA (Ulrich et al., 1998) , feedback inhibition by PKA is likely to play an important role in physiological regulation of secretin receptor responsiveness.
From the present study, the precise role of PKA in regulating secretin receptor desensitization in NG108-15 cells remains unclear. Receptor desensitization by PKA may arise from direct uncoupling of the receptor-eector signalling pathway by receptor phosphorylation, promotion of receptor internalization (Walker et al., 1999) , and/or an involvement of PKA in vesicular transport and resensitization (Goretzki & Mueller, 1997) . As the eect of H-89 in decreasing receptor desensitization was only observed at longer time periods (430 min) of agonist stimulation, PKA-mediated changes in protein synthesis was considered as a potential mechanism. Interestingly, treatment with the protein synthesis inhibitor cycloheximide enhanced secretin receptor responsiveness with a pro®le somewhat similar to that observed with PKA inhibition. This data could be interpreted to indicate that newly synthesized protein(s) may act as accessory molecules to regulate secretin receptor signalling in a PKA-dependent manner. A similar mechanism has been demonstrated for the class II PACAP receptor which undergoes agonist-mediated desensitization by processes involving PKA activation and protein neosynthesis in CATH.a cells (Muller et al., 1998) . In the present study, cycloheximide also enhanced cyclic AMP responses stimulated by NECA and iloprost, but the increases were small in extent when compared to the eects of cycloheximide on secretin responsiveness. The increase in NECA and iloprost responses may re¯ect the eects of protein synthesis inhibition at the level of the receptors or Gproteins, since forskolin responsiveness was unchanged by cycloheximide pretreatment.
In summary, we show that endogenous secretin receptor responsiveness is modulated by PKA, PKC and protein neosynthesis. Furthermore, we present evidence that compartmentalization of GPCR-cyclic AMP signalling occurs in NG108-15 cells. Our future studies will seek to identify the molecular mechanisms underlying second messenger-dependent regulation of secretin receptor responsiveness, and in particular whether the receptor itself is subject to direct regulation by these kinases.
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